[Table_MainInfo] 公司研究/医药与健康护理/医疗保健提供商与服务 证券研究报告 诺禾致源（688315）公司年报点评 [Table_InvestInfo] 盈利能力提升、关注国际贸易环境变化 [Table_Summary] 投资要点： 主要财务数据及预测 | [Table_FinanceInfo] | | | | | | | --- | --- | --- | --- | --- | --- | | 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | 营业收入 | 2,002 | 2,111 | 2,357 | 2,634 | 2,947 | | (+/-)% | 4.0% | 5.5% | 11.6% | 11.8% | 11.9% | | 净利润（归母） | 178 | 197 | 222 | 248 | 276 | | (+/-)% | 0.5% | 10.5% | 12.9% | 11.6% | 11.1% | | 每股净收益（元） | 0.43 | 0.47 | 0.53 | 0.60 | 0.66 | | 净资产收益率(%) ...

4月21日，诺禾致源今日收盘13.94元，上涨1.90%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到28.53倍，创12天以来新低，总市值58.02亿元。 北京诺禾致源科技股份有限公司的主营业务是依托高通量测序技术和生物信息分析技术，建立了通量规 模领先的基因测序平台，并结合多组学研究技术手段，为生命科学基础研究、医学及临床应用研究提供 多层次的科研技术服务及解决方案；同时，基于在基因测序及其应用领域的技术积累，自主开发创新的 基因检测医疗器械。公司的主要产品是生命科学基础科研服务、医学研究与技术服务、建库测序平台服 务。在创新驱动和效率驱动的研发战略导向下，公司搭建了通量规模领先、测序质量稳定、高效交付的 基因测序平台，并始终在各项高难度基因测序技术保持领先地位，全面掌握基因组学、蛋白质组学、代 谢组学及多组学整合研究技术体系，形成从基础研究、转化研究到临床应用的跨领域协同优势，截至 2024年12月31日，诺禾致源联合署名发表或被提及的SCI文章总计30,467余篇，累计影响因子 208,245.37，取得发明专利79项、软件著作权495项。 最新一期业绩显示，2025年一季报，公司实现 ...

股东方面，截至2025年3月31日，诺禾致源股东户数9593户，较上次增加2709户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21诺禾致源27.5328.452.2155.98亿行业平均 45.0541.013.36141.40亿行业中值46.9735.682.4248.61亿1普瑞眼科-185.6423.202.8062.17亿2何氏眼 科-146.8145.011.4828.60亿3光正眼科-92.66220.167.4720.38亿4迪安诊断-92.2327.771.2185.37亿5南华生 物-81.46-107.1912.1430.20亿6创新医疗-42.79-42.792.2640.20亿7国际医学-32.95-32.033.23117.99亿8嘉和 美康-26.93-26.932.2640.40亿9皓宸医疗-22.04-22.704.7821.42亿10美迪西-11.99-11.991.6137.86亿11和元生 物-10.96-10.961.9135.63亿 4月16日，诺禾致源今日收盘13.45元，下跌1.54%，滚动市 ...

Core Insights - The company achieved a revenue of 2.111 billion yuan in 2024, representing a year-on-year increase of 5.45%, and a net profit attributable to shareholders of 197 million yuan, up 10.52% year-on-year [1] - The company is expected to see accelerated revenue and profit growth in 2025 due to steady demand recovery [1][2] Growth Potential - The company experienced a clear quarter-on-quarter improvement in profit growth, with a strong recovery in orders anticipated for 2025 [2] - The establishment of new laboratories in Japan and an expanding overseas laboratory network covering approximately 90 countries is expected to enhance local delivery capabilities and drive high growth in overseas revenue, which accounted for 49.3% of total revenue in 2024 [2] Profitability - The company maintained a gross margin of 43.7% in 2024, an increase of 1.0 percentage points year-on-year, with expectations for high gross margins in 2025 due to automation systems reducing costs and improving efficiency [3] - The net profit margin for 2024 was 9.65%, up 0.50 percentage points year-on-year, with a projected net profit margin of 7.19% for Q1 2025, reflecting ongoing cost reduction and efficiency improvements [4] Financial Forecast - Revenue projections for 2025-2027 are estimated at 2.270 billion, 2.554 billion, and 2.887 billion yuan, with year-on-year growth rates of 7.50%, 12.52%, and 13.03% respectively [5] - Net profit forecasts for the same period are 222 million, 253 million, and 284 million yuan, with corresponding year-on-year growth rates of 12.73%, 14.13%, and 12.19% [5]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see accelerated revenue and profit growth in 2025, driven by a steady recovery in demand [1][2] - The company has made significant progress in overseas expansion, with a laboratory established in Japan and a network covering approximately 90 countries, leading to an increase in overseas revenue contribution [2] - Automation systems are expected to maintain high gross margins, with a projected gross margin of 43.7% for 2024 and a focus on cost reduction and efficiency improvements [3][4] Revenue and Profit Growth - In 2024, the company achieved revenue of 2.111 billion yuan (up 5.45% year-on-year) and a net profit of 197 million yuan (up 10.52% year-on-year) [1] - The first quarter of 2025 showed revenue of 502 million yuan (up 7.2% year-on-year) and a net profit of 34 million yuan (up 24.0% year-on-year), indicating a strong recovery [1] - Revenue projections for 2025-2027 are 2.270 billion, 2.554 billion, and 2.887 billion yuan, representing year-on-year growth rates of 7.50%, 12.52%, and 13.03% respectively [5] Profitability - The gross margin for 2024 is expected to be 43.7%, with a slight decrease to 39.5% in Q1 2025, attributed to ongoing automation and cost reduction efforts [3] - The net margin for 2024 is projected at 9.65%, with an increase to 7.19% in Q1 2025, reflecting continued efficiency improvements [4] Financial Forecast - The company is expected to achieve net profits of 222 million, 253 million, and 284 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.53, 0.61, and 0.68 yuan [5][10]

诺禾致源 20250415 摘要 • 诺禾致源 2024 年营收 5.02 亿元，同比增长 7.16%，海外营收 10.41 亿 元，同比增长 5.69%，占总营收 49.3%，略有提升；2025 年 Q1 海外营 收增速加快，同比增长 8%，环比提升 7.85 个百分点，显示海外市场增长 潜力。 • 公司生命科学基础科研服务和建筑测序平台服务在 2024 年分别实现 17.17 亿元和 10.56 亿元收入，同比增长 12.87%和 10.83%；但 2025 年 Q1 医学研究及技术服务收入同比下降 504%，需关注该业务板块的未 来发展。 • 诺禾致源客户结构中，高校与研究机构占比提升至 62%，而医院与企业类 客户占比下降至 28%，表明公司在科研领域的优势，但需关注企业客户的 拓展。 • 公司整体毛利率提升至 43.74%，同比提升 1.01 个百分点，主要得益于 产品价格稳定、客户分散、议价能力稳定以及高附加值服务比例提升，同 时优化供应链降低了成本。 Q&A 请介绍一下诺和资源公司 2024 年及 2025 年 Q1 的营收情况。 诺和资源公司 2024 年实现营收 21.1 亿元，同比增长 5 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 预计 2025 年日常关联交易的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）首次公开发行 并在科创板上市及 2022 年向特定对象发行股票的持续督导保荐机构，根据《证 券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票上市规则》，对 诺禾致源关于预计 2025 年日常关联交易的议案的事项进行了审慎核查，核查情 况如下： 一、日常关联交易基本情况 2025 年 4 月 14 日，北京诺禾致源科技股份有限公司（以下简称"公司"） 第三届董事会第二十二次会议审议通过《关于预计 2025 年日常关联交易的议 案》，其中《与天津食安居餐饮管理有限公司的关联交易》关联董事李瑞强先生 回避表决，4 位非关联董事全部投票同意；《与北京诺禾心康基因科技有限公司 的关联交易》，关联董事王其锋先生回避表决，4 位非关联 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、审议并通过了《关于公司2024年度财务决算报告的议案》 公司根据2024年实际经营情况编制了《2024年度财务决算报告》。 表决结果：同意3票；反对0票；弃权0票。 本议案尚需提交股东大会审议。 公司拟向全体股东每股派发现金红利0.05元（含税）。截至2024年12月31日，公司总股本416,200,000 股，扣减回购专用证券账户中股份数11,141,468股，以此计算合计拟派发现金红利为人民币 20,252,926.60元（含税）。本年度公司现金分红金额占合并报表中归属于上市公司股东净利润的比例为 10.29%。2024年度公司不送红股，不进行资本公积转增股本。 监事会认为，公司2024年年度利润分配方案，充分考虑了公司盈利情况、现金流量状况和资金需求计 划，结合当前发展阶段、长远发展规划及股东合理回报规划，不存在损害股东利益的情形，有利于公司 持续稳定发展，符合相关法律、法规及《公司章程》的规定。同意该议案，并同意将该议案提交公司 2024年年度股东大会审议。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《北京诺禾致 ...

公司代码：688315 公司简称：诺禾致源 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险，并已在本报告中详细阐述在公司生 产经营过程中可能面临的风险及应对措施，敬请查阅本报告第三节"管理层讨论与分析"之"四、风险因 素"部分内容。 3、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4、公司全体董事出席董事会会议。 5、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 6、公司上市时未盈利且尚未实现盈利 □是 √否 7、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2024年度拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中股份数为基数分 配利润，公司拟向全体股东每股派发现金红利0.05元（含税）。截至2024年12月31日，公司总股本 41 ...

Policy Developments - The National Medical Products Administration (NMPA) approved the registration of 308 medical device products as of March 2025, including 248 domestic Class III medical devices, 34 imported Class III medical devices, 19 imported Class II medical devices, and 7 medical devices from Hong Kong, Macau, and Taiwan [1] Drug Approvals - Chengdu Saijing Bio's ursodeoxycholic acid oral suspension has been approved as the first domestic generic Class 3.1 new drug for treating cystic fibrosis-associated liver disease (CFALD), filling a gap in the market for this indication [2] - Kowa Company's pemafibrate tablets have been approved in China for the treatment of dyslipidemia [3] - Merck Sharp & Dohme (MSD) announced that its nine-valent HPV vaccine has received approval for male use in China, targeting males aged 16-26, enhancing public awareness of HPV infections in men [5] Capital Market - Zhongjie Chaorun completed a Pre-A round financing of several million yuan, primarily for clinical trials of its artificial meniscus implant and commercialization of its innovative meniscus suturing device [4] Financial Reports - Aoyang Health reported a 2024 revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%, with a net profit of 40.56 million yuan, down 18.36% [6] - Novogene announced a total revenue of 2.111 billion yuan for 2024, a year-on-year increase of 5.45%, with a net profit of 197 million yuan, up 10.52% [7] - Tianyi Medical reported a revenue of 419 million yuan for 2024, a year-on-year increase of 9.98%, but a net loss of 744,000 yuan [8] - Luoxin Pharmaceutical disclosed a net loss of 962 million yuan for 2024, despite a revenue increase of 11.99% to 2.647 billion yuan [9] - Dongxing Medical reported a revenue of approximately 435 million yuan for 2024, a slight increase of 0.4%, with a net profit of about 97.42 million yuan, up 0.21% [10] Public Sentiment - Xinbang Pharmaceutical announced the resignation of independent director Zhou Jun, with the company reporting a revenue of 6.032 billion yuan for 2024, down 6.63%, and a net profit of 101 million yuan, down 64.70% [11] - Shuangcheng Pharmaceutical warned of potential delisting risk due to expected negative net profit and revenue below 300 million yuan for 2024 [12]